January 28, 2025

P-Tau217/β-Amyloid Ratio Blood Test Gains Breakthrough Status

FDA designates novel plasma-based Alzheimer's biomarker assay for accelerated review, potentially offering clinicians a less invasive diagnostic alternative to current standards of care.

Conexiant

January 28, 2025

Trial Data Behind FDA Psychiatric Approvals

Key trial data and insights behind US Food and Drug Administration approvals of novel psychiatric drugs are shown, highlighting methods, demographics, and pivotal outcomes.

Conexiant

January 27, 2025

Long-Term Effects of COVID-19 Reinfections

“Each subsequent infection could potentially increase the burden on the immune system, leaving individuals vulnerable to the cumulative effects of the virus."

Conexiant

January 27, 2025

Particulate Matter Prompts Phenylephrine Hydrochloride Recall

Provepharm's urgent nationwide recall warns that contaminated injectable phenylephrine could lead to "serious complications such as stroke or even death" if particulate matter enters blood vessels.

Conexiant

January 27, 2025

FDA Approves New Leqembi Dosing Regimen

Leqembi gains FDA approval for updated intravenous dosing schedule for early Alzheimer’s disease.

Conexiant

January 23, 2025

States Split on Immigration, Hospitals Adapt

“You are instilling fear into folks who may defer care, who may go without care, whose children may not get the vaccines they need, who may not be able to get treatment for an ear infection or surgery."

KFF Health News

January 22, 2025

FDA Warns of Anaphylaxis with MS Drug

MS medication glatiramer acetate (Copaxone, Glatopa), now includes a Boxed Warning for the risk of allergic reactions.

Conexiant

January 21, 2025

Oral Dissolving Film Anticoagulant Trial Results

TAHO Pharmaceuticals completes pivotal trial of the first oral dissolving film anticoagulant, potentially transforming how life-saving therapies are delivered.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant